Cargando…
Cytopenias After CD19 Chimeric Antigen Receptor T-Cells (CAR-T) Therapy for Diffuse Large B-Cell Lymphomas or Transformed Follicular Lymphoma: A Single Institution Experience
INTRODUCTION: Patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) have poor outcomes. Treatment with CD19 chimeric antigen receptor (CAR-T) cells, tisagenlecleucel and axicabtagene ciloleucel, has been associated with improved outcomes. Cytopenias were observed in clinical trials...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8643129/ https://www.ncbi.nlm.nih.gov/pubmed/34876852 http://dx.doi.org/10.2147/CMAR.S321202 |
_version_ | 1784609818285178880 |
---|---|
author | Schaefer, Andrew Huang, Ying Kittai, Adam Maakaron, Joseph E Saygin, Caner Brammer, Jonathan Penza, Sam Saad, Ayman Jaglowski, Samantha M William, Basem M |
author_facet | Schaefer, Andrew Huang, Ying Kittai, Adam Maakaron, Joseph E Saygin, Caner Brammer, Jonathan Penza, Sam Saad, Ayman Jaglowski, Samantha M William, Basem M |
author_sort | Schaefer, Andrew |
collection | PubMed |
description | INTRODUCTION: Patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) have poor outcomes. Treatment with CD19 chimeric antigen receptor (CAR-T) cells, tisagenlecleucel and axicabtagene ciloleucel, has been associated with improved outcomes. Cytopenias were observed in clinical trials with both products; however, little is known regarding the patterns and outcomes of these cytopenias. SUBJECTS AND METHODS: We reviewed DLBCL patients (n=32) receiving either product between January and September 2018 at our institution. RESULTS: Median duration of leukopenia, neutropenia, lymphopenia, anemia, and thrombocytopenia was 49, 9, 117.5, 125, and 95.5 days after CAR-T infusion, respectively. Filgrastim was used in 63% of patients, and 50% of patients received red cell or platelet transfusions. With the exception of neutropenia, increase in the duration of cytopenia of any lineage was associated with improvement in progression-free survival, and in overall survival in case of anemia. There was no association between the duration of cytopenias with either cytokine release syndrome or neurotoxicity. DISCUSSION: Our data suggest a correlation between cytopenias and survival outcomes after CD19 CAR-T therapy. If validated, cytopenia may be proven useful as a biomarker of response and survival after CAR-T therapy. |
format | Online Article Text |
id | pubmed-8643129 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-86431292021-12-06 Cytopenias After CD19 Chimeric Antigen Receptor T-Cells (CAR-T) Therapy for Diffuse Large B-Cell Lymphomas or Transformed Follicular Lymphoma: A Single Institution Experience Schaefer, Andrew Huang, Ying Kittai, Adam Maakaron, Joseph E Saygin, Caner Brammer, Jonathan Penza, Sam Saad, Ayman Jaglowski, Samantha M William, Basem M Cancer Manag Res Original Research INTRODUCTION: Patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) have poor outcomes. Treatment with CD19 chimeric antigen receptor (CAR-T) cells, tisagenlecleucel and axicabtagene ciloleucel, has been associated with improved outcomes. Cytopenias were observed in clinical trials with both products; however, little is known regarding the patterns and outcomes of these cytopenias. SUBJECTS AND METHODS: We reviewed DLBCL patients (n=32) receiving either product between January and September 2018 at our institution. RESULTS: Median duration of leukopenia, neutropenia, lymphopenia, anemia, and thrombocytopenia was 49, 9, 117.5, 125, and 95.5 days after CAR-T infusion, respectively. Filgrastim was used in 63% of patients, and 50% of patients received red cell or platelet transfusions. With the exception of neutropenia, increase in the duration of cytopenia of any lineage was associated with improvement in progression-free survival, and in overall survival in case of anemia. There was no association between the duration of cytopenias with either cytokine release syndrome or neurotoxicity. DISCUSSION: Our data suggest a correlation between cytopenias and survival outcomes after CD19 CAR-T therapy. If validated, cytopenia may be proven useful as a biomarker of response and survival after CAR-T therapy. Dove 2021-11-30 /pmc/articles/PMC8643129/ /pubmed/34876852 http://dx.doi.org/10.2147/CMAR.S321202 Text en © 2021 Schaefer et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research Schaefer, Andrew Huang, Ying Kittai, Adam Maakaron, Joseph E Saygin, Caner Brammer, Jonathan Penza, Sam Saad, Ayman Jaglowski, Samantha M William, Basem M Cytopenias After CD19 Chimeric Antigen Receptor T-Cells (CAR-T) Therapy for Diffuse Large B-Cell Lymphomas or Transformed Follicular Lymphoma: A Single Institution Experience |
title | Cytopenias After CD19 Chimeric Antigen Receptor T-Cells (CAR-T) Therapy for Diffuse Large B-Cell Lymphomas or Transformed Follicular Lymphoma: A Single Institution Experience |
title_full | Cytopenias After CD19 Chimeric Antigen Receptor T-Cells (CAR-T) Therapy for Diffuse Large B-Cell Lymphomas or Transformed Follicular Lymphoma: A Single Institution Experience |
title_fullStr | Cytopenias After CD19 Chimeric Antigen Receptor T-Cells (CAR-T) Therapy for Diffuse Large B-Cell Lymphomas or Transformed Follicular Lymphoma: A Single Institution Experience |
title_full_unstemmed | Cytopenias After CD19 Chimeric Antigen Receptor T-Cells (CAR-T) Therapy for Diffuse Large B-Cell Lymphomas or Transformed Follicular Lymphoma: A Single Institution Experience |
title_short | Cytopenias After CD19 Chimeric Antigen Receptor T-Cells (CAR-T) Therapy for Diffuse Large B-Cell Lymphomas or Transformed Follicular Lymphoma: A Single Institution Experience |
title_sort | cytopenias after cd19 chimeric antigen receptor t-cells (car-t) therapy for diffuse large b-cell lymphomas or transformed follicular lymphoma: a single institution experience |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8643129/ https://www.ncbi.nlm.nih.gov/pubmed/34876852 http://dx.doi.org/10.2147/CMAR.S321202 |
work_keys_str_mv | AT schaeferandrew cytopeniasaftercd19chimericantigenreceptortcellscarttherapyfordiffuselargebcelllymphomasortransformedfollicularlymphomaasingleinstitutionexperience AT huangying cytopeniasaftercd19chimericantigenreceptortcellscarttherapyfordiffuselargebcelllymphomasortransformedfollicularlymphomaasingleinstitutionexperience AT kittaiadam cytopeniasaftercd19chimericantigenreceptortcellscarttherapyfordiffuselargebcelllymphomasortransformedfollicularlymphomaasingleinstitutionexperience AT maakaronjosephe cytopeniasaftercd19chimericantigenreceptortcellscarttherapyfordiffuselargebcelllymphomasortransformedfollicularlymphomaasingleinstitutionexperience AT saygincaner cytopeniasaftercd19chimericantigenreceptortcellscarttherapyfordiffuselargebcelllymphomasortransformedfollicularlymphomaasingleinstitutionexperience AT brammerjonathan cytopeniasaftercd19chimericantigenreceptortcellscarttherapyfordiffuselargebcelllymphomasortransformedfollicularlymphomaasingleinstitutionexperience AT penzasam cytopeniasaftercd19chimericantigenreceptortcellscarttherapyfordiffuselargebcelllymphomasortransformedfollicularlymphomaasingleinstitutionexperience AT saadayman cytopeniasaftercd19chimericantigenreceptortcellscarttherapyfordiffuselargebcelllymphomasortransformedfollicularlymphomaasingleinstitutionexperience AT jaglowskisamantham cytopeniasaftercd19chimericantigenreceptortcellscarttherapyfordiffuselargebcelllymphomasortransformedfollicularlymphomaasingleinstitutionexperience AT williambasemm cytopeniasaftercd19chimericantigenreceptortcellscarttherapyfordiffuselargebcelllymphomasortransformedfollicularlymphomaasingleinstitutionexperience |